Market

India’s Biological E. to begin Phase III trial of vaccine, production from August By Reuters

© Reuters.

By Krishna N. Das

NEW DELHI (Reuters) – India’s Biological E. Ltd will soon start Phase III trials of its COVID-19 vaccine and plans producing 75 million to 80 million doses a month from August, its managing director told Reuters on Friday.

The company has developed the vaccine with Baylor College of Medicine in Houston and Dynavax (NASDAQ:) Technologies Corp. Late last month it received approval from India’s drug regulator to conduct a Phase III clinical trial, which Managing Director Mahima Datla said would begin soon.

Government officials have said the vaccine, which uses the recombinant-protein technology in which a harmless agent is used to stimulate an immune response in cells, could be rolled out in the country from August.

Datla said Biological E. would apply for emergency use authorisation (EUA) for the drug based on government advice.

Production “from August but EUA depends on the government. Will follow their advice and directives,” she said in a text message. “75-80 million doses a month from the time of launch.”

Datla declined to comment on any firm deal to contract-manufacture the Johnson & Johnson (NYSE:) vaccine. She told Reuters in February that Biological E. was looking to make about 600 million doses of the J&J vaccine annually.

J&J said last month it was in talks with India’s government to begin a clinical trial of its single-dose shot.

India, battling the world’s worst jump in coronavirus infections, has partially or fully immunized only about 10% of its 1.35 billion people. It has administered a total of 163 million doses of the AstraZeneca (NASDAQ:) shot and a domestically made one called Covaxin.

The country has also received doses of the Sputnik V vaccine from Russia though it has not been launched yet in the country. India has also urged Pfizer/BioNTech and Moderna (NASDAQ:) to sell their shots to the country.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button